Literature DB >> 3439807

Activity of newer beta-lactam agents against clinical isolates of Bacteroides fragilis and other Bacteroides species.

J P O'Keefe1, F R Venezio, C A DiVincenzo, K L Shatzer.   

Abstract

The in vitro activities of beta-lactam antibiotics against Bacteroides fragilis and B. fragilis group isolates are presented. Clinical isolates from 1986 were compared with strains from 1979 to 1982. Imipenem, ticarcillin-clavulanic acid, and ceftizoxime were the most active agents. Cefotetan was equivalent to cefoxitin against B. fragilis but less active against B. fragilis group isolates. Enhancement of cefotaxime by its desacetyl metabolite was minimal.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3439807      PMCID： PMC175843          DOI： 10.1128/AAC.31.12.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Susceptibility of anaerobes to cefoxitin and other cephalosporins.

Authors:  F P Tally; N V Jacobus; J G Bartlett; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1975-02       Impact factor: 5.191

2.  Activity of cefazolin and two beta-lactamase inhibitors, clavulanic acid and sulbactam, against Bacteroides fragilis.

Authors:  T Fekete; J McGowen; K R Cundy
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

3.  Randomized prospective study comparing moxalactam and cefoxitin with or without tobramycin for the treatment of serious surgical infections.

Authors:  F P Tally; J M Kellum; J L Ho; T F O'Donnell; M Barza; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

4.  Clinical pharmacokinetics of cefotaxime in patients with normal and reduced renal function.

Authors:  J T Doluisio
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

5.  Prospective, randomized, comparative trials in the therapy for intraabdominal and female genital tract infections.

Authors:  G K Harding; L E Nicolle; D A Haase; F Y Aoki; H G Stiver; R J Blanchard; J R Kirkpatrick
Journal:  Rev Infect Dis       Date:  1984 Mar-Apr

6.  Antimicrobial activity of desacetylcefotaxime alone and in combination with cefotaxime: evidence of synergy.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

7.  Comparative clinical evaluation of ceftizoxime with clindamycin and gentamicin and cefoxitin in the treatment of postcesarean endomyometritis.

Authors:  J J Apuzzio; V Ganesh; M A Pelosi; I Landau; H A Kaminetzky; Z Kaminski; D B Louria
Journal:  Surg Gynecol Obstet       Date:  1985-12

8.  Antimicrobial susceptibilities of 1,292 isolates of the Bacteroides fragilis group in the United States: comparison of 1981 with 1982.

Authors:  G J Cuchural; F P Tally; N V Jacobus; S L Gorbach; K Aldridge; T Cleary; S M Finegold; G Hill; P Iannini; J P O'Keefe
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

9.  Nationwide study of the susceptibility of the Bacteroides fragilis group in the United States.

Authors:  F P Tally; G J Cuchural; N V Jacobus; S L Gorbach; K Aldridge; T Cleary; S M Finegold; G Hill; P Iannini; J P O'Keefe
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

10.  A randomized comparison of cefoxitin with or without amikacin and clindamycin plus amikacin in surgical sepsis.

Authors:  F P Tally; K McGowan; J M Kellum; S L Gorbach; T F O'Donnell
Journal:  Ann Surg       Date:  1981-03       Impact factor: 12.969
View more
  7 in total

1.  Spiral gradient endpoint method compared to standard agar dilution for susceptibility testing of anaerobic gram-negative bacilli.

Authors:  G B Hill
Journal:  J Clin Microbiol       Date:  1991-05       Impact factor: 5.948

2.  In vitro susceptibilities of the Bacteroides fragilis group to 14 antimicrobial agents in Korea.

Authors:  K Lee; I H Jang; Y J Kim; Y Chong
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 3.  Ceftizoxime: a third-generation cephalosporin active against anaerobic bacteria. Committee on Antimicrobial Agents, Canadian Infectious Disease Society.

Authors: 
Journal:  CMAJ       Date:  1990-06-01       Impact factor: 8.262

4.  Effect of beta-lactamase inhibitors on the activities of various beta-lactam agents against anaerobic bacteria.

Authors:  H M Wexler; E Molitoris; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

5.  Comparative in vitro antimicrobial susceptibilities of a special panel of 74 Bacteroides fragilis group isolates in Wilkins-Chalgren agar with and without sheep blood.

Authors:  C J Gill; D L Shungu; S Ponticas
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

6.  Longitudinal study of susceptibilities of species of the Bacteroides fragilis group to five antimicrobial agents in three medical centers.

Authors:  P Turgeon; V Turgeon; M Gourdeau; J Dubois; F Lamothe
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

7.  Annual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime of recent community-acquired isolates of the Bacteroides fragilis group.

Authors:  E J Goldstein; D M Citron
Journal:  J Clin Microbiol       Date:  1988-11       Impact factor: 5.948
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.